2,115 press releases in English indexed under biotech & pharma.
The registrational Phase III study of the mesutoclax regime versus venetoclax regime in elderly or unfit patients with TN AML has been approved in China.
Investors who lost money in REGN after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
Investors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
SAN DIEGO, Aug. 17, 2026 -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class...
Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –
SAN DIEGO, Aug. 17, 2026 -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's...
Victoria,Seychelles, Aug. 17, 2026 -- Zoomex has expanded its Stock Perpetuals lineup with twelve new USDT-margined contracts, giving traders 24/7 exposure to some of the most closely watched names in U.S. equities. UnitedHealth Group (UNH), General Electric (GE), JPMorgan Chase (JPM), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Walmart (WMT), Coca-Cola (KO), PepsiCo (PEP), Mastercard (MA), PayPal Holdings (PYPL), and Berkshire Hathaway Class B (BRK.B) are now live for long and short positions, with no traditional market hours required.
San Diego, California--(August 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company's lead product...
FOSTER CITY, Calif., Aug. 17, 2026 -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.
RESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.
MILWAUKEE, Aug. 17, 2026 -- The Society for Immunotherapy of Cancer (SITC) is proud to announce the 2026 Class of Fellows of the Academy of Immuno-Oncology (FAIO), recognizing internationally renowned leaders whose pioneering discoveries and enduring contributions have...